Pharmaceutical composition for preventing and treating HPV (human papillomavirus) and cervical cancer and preparation method thereof

By combining immune cell lysing proteins and morrhagic ketone complex with duraglutide, the problem of poor efficacy and severe side effects in existing HPV and cervical cancer treatments has been solved, achieving effective inhibition and proliferation of cervical cancer cells, and has broad application prospects.

CN119015399AInactive Publication Date: 2024-11-26HANGZHOU AXO BIOTECHNOLOGY CO LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202411514171.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-29
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing technologies for the prevention and treatment of HPV and cervical cancer have shortcomings such as poor drug efficacy, significant side effects, and complex preparation processes, and there is a lack of highly effective and safe drug compositions.

Method used

A combination of immune cell lysing protein, morrhuate complex, and duraglutide was used to prepare CIK cell lysing protein and morrhuate complex, which synergistically inhibited the proliferation of cervical cancer cells and reduced toxic side effects.

Benefits of technology

It has achieved effective inhibition and proliferation of cervical cancer cells, reduced the toxic side effects of single drugs, and has broad application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015399A_ABST
    Figure CN119015399A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to a pharmaceutical composition for preventing and treating HPV (human papillomavirus) and cervical cancer and a preparation method of the pharmaceutical composition. The pharmaceutical composition for preventing and treating the HPV and the cervical cancer is prepared from the following components in parts by weight: 1 to 1.5 parts of immune cell lysis protein, 0.5 to 1 part of fraxinellone compound and 0.3 to 0.7 part of doraglutide. The immune cell cleavage protein, the fraxinellone compound and the doraglutide in the composition can achieve a synergistic effect, proliferation of cervical cancer cells is effectively inhibited, and cervical cancer is prevented and treated. In addition, the combined use of all the components in the composition can reduce the toxic and side effects of a single drug, and the composition has a wide application prospect in the aspect of treating cervical cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a pharmaceutical composition for preventing and treating HPV and cervical cancer and a preparation method thereof. Background Art

[0002] HPV (human papillomavirus) is a widely distributed virus that can cause squamous epithelial proliferation in the skin and mucous membranes of the human body, leading to cervical cancer. According to the pathogenic risk of the virus, HPV is divided into two categories: high-risk and low-risk. High-risk HPV, especially HPV16 and HPV18, are closely related to the occurrence of malignant tumors such as cervical cancer. They play a vital role in the occurrence of cervical cancer. Through their specific gene products (such as E6 and E7 proteins), they integrate with the DNA of host cells, interfere with the normal growth and differentiation process of cells, inhibit the function of tumor suppressor genes, and promote abnormal proliferation and carcinogenesis of cells.

[0003] At present, the treatment methods for cervical cancer include surgical treatment, radiotherapy, chemotherapy and immunotherapy. Among them, immunotherapy has attracted much attention in recent years due to its unique mechanism. With the continuous development of immunology, immune cell therapy has become an important research direction in the field of tumor treatment. By activating or enhancing the patient's own immune system, especially immune cells such as T cells and natural killer cells (NK cells), HPV-infected cells and early cancerous cells can be specifically identified and eliminated, providing a new strategy for the treatment of HPV infection and cervical cancer.

[0004] Although the current technology for preventing and treating HPV and cervical cancer has made significant progress, there are still some shortcomings, which are mainly reflected in the following aspects: poor drug efficacy, large side effects, and complex preparation process.

[0005] As one of the active ingredients in Dictamni cortex, taufenone has potential anti-tumor effects. Dulaglutide, as a biological agent that has been used to treat other diseases, can not only effectively regulate the immune response mechanism and inhibit inflammatory response, but also has potential anti-tumor and anti-viral effects. However, there are no reports on the use of taufenone and taufenone for the prevention and treatment of HPV and cervical cancer. Based on the above background, the present invention develops a novel, efficient and safe pharmaceutical composition for the prevention and treatment of HPV infection and cervical cancer. Summary of the invention

[0006] The first object of the present invention is to provide a pharmaceutical composition for preventing and treating HPV and cervical cancer.

[0007] In order to achieve the above object, the technical solution adopted by the present invention is: A pharmaceutical composition for preventing and treating HPV and cervical cancer comprises, by weight, 1-1.5 parts of immune cell lysis protein, 0.5-1 parts of ash ketone complex, and 0.3-0.7 parts of dulaglutide.

[0008] Furthermore, the specific preparation process of the immune cell lysis protein is as follows: (1) Isolation and acquisition of immune cells; (2) centrifuging the culture supernatant of the immune cells in step (1) three times, and resuspending the cell pellet after the third centrifugation to obtain the immune cell extracellular matrix protein; (3) The immune cells obtained in step (1) are repeatedly frozen and thawed to obtain cell lysate protein; the cell lysate protein and the immune cell extracellular matrix protein obtained in step (2) are mixed in equal amounts and added to saline to obtain the product.

[0009] Furthermore, the immune cells are CIK cells separated and cultured from human peripheral blood.

[0010] Furthermore, the method for obtaining CIK cells is as follows: S1. Dilute human peripheral blood with PBS buffer and then add it to the lymphocyte separation solution. After centrifugation, aspirate the middle white film layer, wash, and collect peripheral blood mononuclear cells; S2. Adjust the concentration of peripheral blood mononuclear cells with culture medium, add IFN-γ and culture for 24 hours, then add CD3 monoclonal antibody and recombinant human IL-2, and add culture medium containing CD3 monoclonal antibody and recombinant human IL-2 every 2 days, culture for 13-15 days to obtain CIK cells.

[0011] Furthermore, the concentration of the mononuclear cells in the culture medium in step S2 is 1-5×10 6 / mL, the concentration of IFN-γ in the culture medium is 800-1000U / mL, the concentration of CD3 monoclonal antibody in the culture medium is 40-60ng / mL, and the concentration of recombinant human IL-2 in the culture medium is 500-800U / mL.

[0012] Furthermore, the preparation process of the ash ketone complex comprises the following steps: The ash ketone is added to the hydroxyethyl-β-cyclodextrin aqueous solution, and the mixture is homogenized by ultrasound and then oscillated to obtain a mixed solution; the mixed solution is allowed to stand, centrifuged, and the supernatant is taken for freeze-drying to obtain the product.

[0013] Furthermore, the mass ratio of ash ketone to hydroxyethyl-β-cyclodextrin is 1:35-40, and the concentration of the hydroxyethyl β-cyclodextrin aqueous solution is 0.15-0.2 g / mL.

[0014] Furthermore, the power of the ultrasound is 200-300W, and the oscillation time is 24-48h.

[0015] Furthermore, the cervical cancer is cervical cancer caused by HPV16 and / or HPV18 infection.

[0016] The second object of the present invention is to provide a method for preparing a pharmaceutical composition for preventing and treating HPV and cervical cancer.

[0017] In order to achieve the above object, the technical solution adopted by the present invention is: The preparation method of the above-mentioned pharmaceutical composition for preventing and treating HPV and cervical cancer comprises the following steps: The immune cell lysate protein, ash ketone complex and dulaglutide are uniformly mixed according to the above weight portions to obtain the product.

[0018] The beneficial technical effects of the present invention are: (1) Synergistic effect: The immune cell lysis protein, ash ketone complex, and dulaglutide in the composition of the present invention can work synergistically to effectively inhibit the proliferation of cervical cancer cells and prevent and treat cervical cancer.

[0019] (2) Reducing the toxic and side effects of a single drug: The combination of immune cell lytic protein with ash ketone complex and dulaglutide can reduce the toxic and side effects of a single drug.

[0020] (3) Application prospects: The composition of the present invention has broad application prospects in the prevention and treatment of HPV and cervical cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 This is a morphological diagram of CIK cells obtained in Example 1 of the present invention; Figure 2 This is a morphological diagram of CIK cells obtained in Example 2 of the present invention; Figure 3 This is a morphological diagram of CIK cells obtained in Example 3 of the present invention; Figure 4 The effects of different treatment groups of the present invention on the expression levels of E6 / E7 proteins in HeLa cells; Figure 5 This is the effect of different treatment groups of the present invention on the expression level of E6 / E7 proteins in SiHa cells. DETAILED DESCRIPTION

[0022] Below, the present invention is further described in conjunction with specific embodiments. It should be noted that, under the premise of no conflict, the embodiments described below or the technical features can be arbitrarily combined to form new embodiments. The reagents or instruments used, unless otherwise specified, are conventional products obtained through commercial channels.

[0023] Example 1 A pharmaceutical composition for preventing and treating HPV and cervical cancer comprises the following components in parts by weight: 1.2 parts of immune cell lysis protein, 0.8 parts of ash ketone complex, and 0.5 parts of dulaglutide.

[0024] The specific preparation process of the above immune cell lysis protein is as follows: (1) Isolation and culture of immune cells: S1. Take 50mL of human peripheral blood and add heparin anticoagulation, dilute the peripheral blood with an equal volume of PBS buffer, and then add it to the lymphocyte separation solution (the volume ratio of lymphocyte separation solution, peripheral blood, and PBS buffer is 1:1:1), try to avoid mixing the blood sample with the separation solution, and keep the interface between the two liquids clear. Centrifuge at room temperature (500×g, 15min), carefully aspirate the middle white film layer, and wash it with PBS buffer 3 times to obtain peripheral blood mononuclear cells; S2. Adjust the concentration of peripheral blood mononuclear cells to 3×10 using RPMI 1640 medium containing 5% fetal bovine serum. 6 / mL, add recombinant human IFN-γ (900U / mL) and culture for 28h, then add CD3 monoclonal antibody (50ng / mL) and recombinant human IL-2 (600U / mL), add culture medium containing 50ng / mL CD3 monoclonal antibody and 600U / mL recombinant human IL-2 every 2 days, culture for 14 days, obtain CIK cells, and observe their morphological characteristics under a microscope, such as Figure 1 shown.

[0025] (2) Take 50 mL of the culture supernatant of CIK cells in step (1) and place it in a centrifuge. Centrifuge at 3500 rpm for 20 min. The cells or cell fragments in the lower layer will be used in step (3). Add the supernatant to a new centrifuge tube and continue centrifuging at 10000 rpm for 35 min. Then transfer the supernatant after centrifugation to another centrifuge tube and centrifuge at 50000 rpm for 2.5 h. Carefully remove the supernatant, add 0.1 mL of sterilized saline to the cell pellet obtained by the last centrifugation, blow and resuspend, and obtain the immune cell extracellular matrix protein; (3) The cells after the first centrifugation in step (2) are subjected to repeated freeze-thaw treatment (freezing at low temperature and then rapidly thawing) for three times to obtain cell lysate protein. Then, equal amounts of the cell lysate protein and the immune cell extracellular matrix protein obtained in step (2) are mixed and added to 2 mL of saline to obtain the product.

[0026] The preparation process of the above-mentioned ash ketone complex comprises the following steps: First, weigh 0.375g of hydroxyethyl-β-cyclodextrin and add it to 2mL of water, mix it evenly by ultrasonication, and obtain a hydroxyethyl-β-cyclodextrin aqueous solution. Then add 10mg of ash ketone to the hydroxyethyl-β-cyclodextrin aqueous solution, ultrasonicate it at 250W for 20min, and shake it on a constant temperature shaker at 37℃ for 36h to obtain a mixed solution. Let the mixed solution stand at room temperature, centrifuge it, and take the supernatant and freeze-dry it in vacuum to obtain the product.

[0027] This embodiment also provides a method for preparing the above-mentioned pharmaceutical composition for preventing and treating HPV and cervical cancer, comprising the following steps: The immune cell lysate protein, ash ketone complex and dulaglutide are uniformly mixed according to the above weight portions to obtain the product.

[0028] Example 2 A pharmaceutical composition for preventing and treating HPV and cervical cancer comprises the following components in parts by weight: 1 part of immune cell lysis protein, 0.5 part of ash ketone complex, and 0.3 part of dulaglutide.

[0029] The specific preparation process of the above immune cell lysis protein is as follows: (1) Isolation and acquisition of CIK cells: S1. Take 50mL of human peripheral blood and add heparin anticoagulation, dilute the peripheral blood with an equal volume of PBS buffer, and then add it to the lymphocyte separation solution (the volume ratio of lymphocyte separation solution, peripheral blood, and PBS buffer is 1:1:1), try to avoid mixing the blood sample with the separation solution, and keep the interface between the two liquids clear. Centrifuge at room temperature (500×g, 15min), carefully aspirate the middle white film layer, and wash it with PBS buffer 3 times to obtain peripheral blood mononuclear cells; S2. Adjust the concentration of peripheral blood mononuclear cells to 1×10 using RPMI 1640 medium containing 5% fetal bovine serum. 6 / mL, add recombinant human IFN-γ (800U / mL) and culture for 24h, then add CD3 monoclonal antibody (40ng / mL) and recombinant human IL-2 (500U / mL), add culture medium containing 40ng / mL CD3 monoclonal antibody and 500U / mL recombinant human IL-2 every 2 days, culture for 13 days, obtain CIK cells, and observe their morphological characteristics under a microscope, such as Figure 2 shown.

[0030] (2) Take 50 mL of the culture supernatant of CIK cells in step (1) and place it in a centrifuge. Centrifuge at 3500 rpm for 20 min. The cells or cell fragments in the lower layer will be used in step (3). Add the supernatant to a new centrifuge tube and centrifuge at 10000 rpm for 35 min. Then transfer the supernatant after centrifugation to another centrifuge tube and centrifuge at 50000 rpm for 2.5 h. Carefully remove the supernatant, add 0.1 mL of sterilized saline to the cell pellet obtained by the last centrifugation, blow and resuspend, and obtain the immune cell extracellular matrix protein; (3) The cells after the first centrifugation in step (2) are subjected to repeated freeze-thaw treatment three times (freezing at low temperature and then rapidly thawing) to obtain cell lysate protein, and then the cell lysate protein and the immune cell extracellular matrix protein obtained in step (2) are mixed in equal amounts and added to 2 mL of saline to obtain.

[0031] The preparation process of the above-mentioned ash ketone complex comprises the following steps: First, weigh 0.3 g of hydroxyethyl β-cyclodextrin and add it to 2 mL of water, mix it evenly by ultrasonication, and obtain a hydroxyethyl β-cyclodextrin aqueous solution. Then add 10 mg of ash ketone to the hydroxyethyl β-cyclodextrin aqueous solution, ultrasonicate it at 200 W for 20 min, and shake it on a constant temperature shaker at 37°C for 48 h to obtain a mixed solution. Let the mixed solution stand at room temperature, centrifuge it, and take the supernatant and vacuum freeze-dry it to obtain the product.

[0032] This embodiment also provides a method for preparing the above-mentioned pharmaceutical composition for preventing and treating HPV and cervical cancer, comprising the following steps: The immune cell lysate protein, ash ketone complex and dulaglutide are uniformly mixed according to the above weight portions to obtain the product.

[0033] Example 3 A pharmaceutical composition for preventing and treating HPV and cervical cancer comprises the following components in parts by weight: 1.5 parts of immune cell lysis protein, 1 part of ash ketone complex, and 0.7 parts of dulaglutide.

[0034] The specific preparation process of the above immune cell lysis protein is as follows: (1) Isolation and acquisition of CIK cells: S1. Take 50mL of human peripheral blood and add heparin anticoagulation, dilute the peripheral blood with an equal volume of PBS buffer, and then add it to the lymphocyte separation solution (the volume ratio of lymphocyte separation solution and peripheral blood: PBS buffer is 1:1:1), try to avoid mixing the blood sample with the separation solution, and keep the interface between the two liquids clear. Centrifuge at room temperature (500×g, 15min), carefully aspirate the middle white film layer, and wash it with PBS buffer 3 times to obtain peripheral blood mononuclear cells; S2. Adjust the concentration of peripheral blood mononuclear cells to 5×10 using RPMI 1640 medium containing 5% fetal bovine serum. 6 / mL, add recombinant human IFN-γ (1000U / mL) and culture for 30h, then add CD3 monoclonal antibody (60ng / mL) and recombinant human IL-2 (800U / mL), add culture medium containing 60ng / mL CD3 monoclonal antibody and 800U / mL recombinant human IL-2 every 2 days, culture for 15 days, obtain CIK cells, and observe their morphological characteristics under a microscope, such as Figure 3 shown.

[0035] (2) Take 50 mL of the culture supernatant of CIK cells in step (1) and place it in a centrifuge. Centrifuge at 3500 rpm for 20 min. The cells or cell fragments in the lower layer will be used in step (3). Add the supernatant to a new centrifuge tube and centrifuge at 10000 rpm for 35 min. Then transfer the supernatant after centrifugation to another centrifuge tube and centrifuge at 50000 rpm for 2.5 h. Carefully remove the supernatant, add 0.1 mL of sterilized saline to the cell pellet obtained by the last centrifugation, blow and resuspend, and obtain the immune cell extracellular matrix protein; (3) The cells after the first centrifugation in step (2) are subjected to repeated freeze-thaw treatment three times (freezing at low temperature and then rapidly thawing) to obtain cell lysate protein, and then the cell lysate protein and the immune cell extracellular matrix protein in step (2) are mixed in equal amounts and added to 2 mL of saline to obtain.

[0036] The preparation process of the above-mentioned ash ketone complex comprises the following steps: First, weigh 0.40 g of hydroxyethyl β-cyclodextrin and add it to 2 mL of water to obtain a hydroxyethyl β-cyclodextrin aqueous solution. Then add 10 mg of ash ketone to the hydroxyethyl β-cyclodextrin aqueous solution, ultrasonicate at 300 W for 20 min, and shake on a constant temperature shaker at 37°C for 48 h to obtain a mixed solution. The mixed solution is allowed to stand at room temperature, centrifuged, and the supernatant is vacuum freeze-dried to obtain the product.

[0037] This embodiment also provides a method for preparing the above-mentioned pharmaceutical composition for preventing and treating HPV and cervical cancer, comprising the following steps: The immune cell lysate protein, ash ketone complex and dulaglutide are uniformly mixed according to the above weight portions to obtain the product.

[0038] Comparative Example 1 This comparative example 1 provides a pharmaceutical composition for preventing and treating HPV and cervical cancer, which is different from Example 1 in that the ash ketone complex is omitted in the composition.

[0039] Comparative Example 2 This comparative example 2 provides a pharmaceutical composition for preventing and treating HPV and cervical cancer, which differs from Example 1 in that dulaglutide is omitted from the composition.

[0040] Comparative Example 3 Comparative Example 3 provides a pharmaceutical composition for preventing and treating HPV and cervical cancer, which differs from Example 1 in that CIK cell lysis protein and ash ketone complex are omitted, and the dosage of dulaglutide is adjusted to 2.5 parts.

[0041] Test Example 1 Human cervical cancer HeLa cells (HPV18 positive) and SiHa cells (HPV16 positive) in logarithmic growth phase were selected and resuspended in complete culture medium to prepare cell suspensions. 4 The cells were inoculated into 96-well plates at a density of 100 / mL and cultured in a 37°C, 5% CO2 incubator.

[0042] The compositions of Examples 1 to 3 and Comparative Examples 1 to 3 in this application were used as experimental groups, and were divided into Example 1 group according to the different compositions: the final concentrations of the composition of Example 1 in the complete culture medium were adjusted to 10µg / mL, 20µg / mL, 40µg / mL, and 80µg / mL, respectively; Example 2 group, Example 3 group, Comparative Example 1 group, Comparative Example 2 group, and Comparative Example 3 group were the same as Example 1 group. A blank control group was set without any treatment, and 3 duplicate wells were set in each group, and then incubated for 72 hours at the above temperature. The culture medium was discarded, 10µL of MTT solution (5mg / mL) was added to each well, and the culture was continued at 37°C for 4 hours, the culture medium was discarded, 150µL of DMSO was added, and the culture was shaken for 10 minutes, and then the absorbance value of each well at a wavelength of 570nm was detected using an ELISA instrument, and the cell proliferation inhibition rate (%) was calculated as [1-(absorbance value of the experimental group / absorbance value of the blank control group)] × 100%, and the experimental results are shown in Tables 1 and 2.

[0043] Table 1 Inhibition rate of HeLa cell proliferation in each experimental group Table 2 Inhibition rate of SiHa cell proliferation in each experimental group From the experimental results in Tables 1 and 2, it can be seen that the compositions described in Examples 1 to 3 of the present invention show obvious inhibitory effects on SiHa and HeLa cells, and can well inhibit the growth and proliferation of cervical cancer cells. After the ash ketone complex and dulaglutide are omitted in Comparative Examples 1 and 2, respectively, the inhibitory effects of the compositions on SiHa and HeLa cells are weakened, indicating that the ash ketone complex and dulaglutide can both inhibit the proliferation of SiHa and HeLa cells. The inhibitory effect of the composition described in Comparative Example 3 is better than that of Comparative Examples 1 and 2, but inferior to that of Example 1, indicating that the CIK cell lysis protein, ash ketone complex, and dulaglutide in the composition can work synergistically to effectively inhibit the proliferation of cervical cancer cells and prevent and treat cervical cancer.

[0044] Test Example 2 HeLa cells (HPV18 positive) and SiHa cells (HPV16 positive) in the logarithmic growth phase were selected and resuspended in liquid culture medium containing 10% FBS to prepare cell suspensions. 5 The cells were inoculated into a 6-well plate at a density of cells / mL and cultured until the cells adhered to the wall. The composition of Examples 1 to 3 and Comparative Examples 1 to 3 was added to each well, and the concentration in the culture medium was adjusted to 30 µg / mL. An equal amount of sterile saline was added to the control group. After 48 hours of culture, the cells were collected, and the protein in each well was extracted using the BCA method. The protein samples were mixed with 5×Loading Buffer and denatured at 100°C for 10 minutes. The protein samples treated with the above Examples 1 to 3 and Comparative Examples 1 to 3 were added to SDS-PAGE gel for electrophoresis separation. After transfer, blocking, and antibody incubation, the samples were developed using a chemiluminescent reaction solution to detect the expression of E6 / E7 protein in the cells. The results are as follows. Figure 4 , Figure 5 shown.

[0045] Depend on Figure 4 and 5 It can be seen that compared with the control group, after being treated with the composition described in Examples 1 to 3, the protein expression in HeLa cells and SiHa cells was significantly reduced, and the protein expression in Comparative Examples 1 and 2 groups was reduced, indicating that the truncatone complex and dulaglutide in the composition both have an inhibitory effect on the expression of HPV E6 and E7. The protein expression in Comparative Example 3 group was slightly higher than that in Example 1, indicating that the inhibitory effect of the composition of Comparative Example 3 on HPV is not as good as that in Example 1. The above results show that the CIK cell lysis protein, truncatone complex, and dulaglutide in the compositions of Examples 1-3 can work synergistically to inhibit the expression of E6 and E7 proteins in HeLa and SiHa cells.

[0046] Test Example 3 Mouse grouping: SPF 6-week-old Balb / c mice were selected and adaptively raised in an environment of 25°C and 50% relative humidity for 1 week, during which they received normal diet and water.

[0047] Model construction: HeLa cells and SiHa cells were cultured in DMEM medium (containing 10% fetal bovine serum) at 37°C and 5% CO2. Cells in the logarithmic growth phase were digested with 0.25% trypsin and then resuspended in sterilized saline to obtain a density of 2×10 7 / mL of cell suspension, and after iodine disinfection, inoculate 0.2mL of the above cell suspension subcutaneously on the back of the neck of each mouse. Observe the injection site of the mouse every day for redness, swelling, ulceration, etc. After 2 weeks of injection, two HeLa cell and SiHa cell transplanted tumor mouse models were established.

[0048] Administration: On the 15th day, the above two cell transplanted tumor mouse models were divided into Example 1 group, Example 2 group, Example 3 group, Comparative Example 1 group, Comparative Example 2 group, and Comparative Example 3 group, with 10 mice in each group, and the corresponding composition was gavage at a dose of 50 mg / kg; the model group was given an equal amount of normal saline once a day, and the mice were killed by cervical dislocation after continuous injection for 21 days, the tumor tissue was completely peeled off, the tumor weight of the mice was weighed, and the tumor inhibition rate was calculated, tumor inhibition rate (%) = (1-average tumor weight of the experimental group / average tumor weight of the model group) × 100%. The effects of the compositions of Examples 1 to 3 and Comparative Examples 1 to 3 on the tumor weight of HeLa cell transplanted tumors are shown in Table 3, and the effects of the compositions of Examples 1 to 3 and Comparative Examples 1 to 3 on the tumor weight of SiHa cell transplanted tumors are shown in Table 4.

[0049] Table 3 Effects of the compositions of Examples 1 to 3 and Comparative Examples 1 to 3 on the weight of HeLa cell transplanted tumors Table 4 Effects of the compositions of Examples 1 to 3 and Comparative Examples 1 to 3 on the weight of SiHa cell transplanted tumors As shown in Table 3, the tumor weight of mice in Example 1-3 groups was significantly reduced compared with the model group, wherein the tumor inhibition rate of Example 1 could reach 65.28%, with a good tumor inhibition effect, the tumor inhibition rates of Comparative Example 1 and Comparative Example 2 were 36.57% and 40.28%, respectively, and the tumor inhibition rate of Comparative Example 3 was 50.00%. As shown in Table 4, the tumor weight of mice in Example 1-3 groups was significantly reduced compared with the model group, wherein the tumor inhibition rate of Example 1 could reach 57.52%, with a good tumor inhibition effect, the tumor inhibition rates of Comparative Example 1 and Comparative Example 2 were 25.49% and 30.72%, respectively, and the tumor inhibition rate of Comparative Example 3 was 39.87%. The above experimental results show that CIK cell lysis protein, ash ketone complex, and dulaglutide can act synergistically in the composition to inhibit the growth of human cervical cancer nude mouse transplanted tumors.

[0050] The above-mentioned embodiments are only preferred embodiments of the present invention and cannot be used to limit the scope of protection of the present invention. Any non-substantial changes and substitutions made by technicians in this field on the basis of the present invention shall fall within the scope of protection required by the present invention.

Claims

1. A pharmaceutical composition for preventing and treating HPV and cervical cancer, It is characterized in that Calculated by weight, it includes 1-1.5 parts of immune cell lysis protein, 0.5-1 parts of ash ketone complex, and 0.3-0.7 parts of dulaglutide.

2. The pharmaceutical composition for preventing and treating HPV and cervical cancer according to claim 1, It is characterized in that The preparation process of the immune cell lysis protein is as follows: (1) Isolation and acquisition of immune cells; (2) centrifuging the culture supernatant of the immune cells in step (1) three times, and resuspending the cell pellet after the third centrifugation to obtain the immune cell extracellular matrix protein; (3) The immune cells obtained in step (1) are repeatedly frozen and thawed to obtain cell lysate protein; the cell lysate protein and the immune cell extracellular matrix protein obtained in step (2) are mixed in equal amounts and added to saline to obtain the product.

3. The pharmaceutical composition for preventing and treating HPV and cervical cancer according to claim 2, It is characterized in that The immune cells are CIK cells separated and cultured from human peripheral blood.

4. The pharmaceutical composition for preventing and treating HPV and cervical cancer according to claim 3, It is characterized in that The method for obtaining the CIK cells is as follows: S1. Dilute human peripheral blood with PBS buffer and then add it to the lymphocyte separation solution. After centrifugation, aspirate the middle white film layer, wash, and collect peripheral blood mononuclear cells; S2. Adjust the concentration of peripheral blood mononuclear cells with culture medium, add IFN-γ and culture for 24-30 hours, then add CD3 monoclonal antibody and recombinant human IL-2; add culture medium containing CD3 monoclonal antibody and recombinant human IL-2 every 2 days, culture for 13-15 days, and obtain CIK cells.

5. The pharmaceutical composition for preventing and treating HPV and cervical cancer according to claim 4, It is characterized in that The concentration of mononuclear cells in the culture medium in step S2 is 1-5×10 6 / mL, the concentration of IFN-γ in the culture medium is 800-1000U / mL, the concentration of CD3 monoclonal antibody in the culture medium is 40-60ng / mL, and the concentration of recombinant human IL-2 in the culture medium is 500-800U / mL.

6. The pharmaceutical composition for preventing and treating HPV and cervical cancer according to claim 1, It is characterized in that The preparation process of the ash ketone complex comprises the following steps: The ash ketone is added to the hydroxyethyl-β-cyclodextrin aqueous solution, and the mixture is homogenized by ultrasound and then oscillated to obtain a mixed solution; the mixed solution is allowed to stand, centrifuged, and the supernatant is taken for freeze-drying to obtain the product.

7. The pharmaceutical composition for preventing and treating HPV and cervical cancer according to claim 6, It is characterized in that The mass ratio of ash ketone to hydroxyethyl-β-cyclodextrin is 1:35-40, and the concentration of the hydroxyethyl-β-cyclodextrin aqueous solution is 0.15-0.2 g / mL.

8. The pharmaceutical composition for preventing and treating HPV and cervical cancer according to claim 6, It is characterized in that The power of the ultrasound is 200-300W, and the oscillation time is 24-48h.

9. The pharmaceutical composition for preventing and treating HPV and cervical cancer according to claim 1, It is characterized in that The cervical cancer is cervical cancer caused by HPV16 and / or HPV18 infection.

10. A method for preparing a pharmaceutical composition for preventing and treating HPV and cervical cancer according to any one of claims 1 to 9, It is characterized in that The steps include: The immune cell lysate protein, ash ketone complex and dulaglutide are uniformly mixed according to the above weight portions to obtain the product.

Citation Information

Patent Citations

  • Method for cultivating lymph-node autologous CIK (cytokine-induced killer) cells and application of lymph-node autologous CIK cells

    CN105154399A

  • Preparation method of DC-CIK cell and application of DC-CIK cell in preparation of medicines for treating ovarian cancer

    CN106811442A

  • Application of fraxinellone in preparation of antitumor drug sensitizer

    CN106924243A

  • Medicine composition for treating cervical cancer and preparation method of medicine composition

    CN111166752A

  • Application of doraglutide to medicine for treating and preventing intrauterine adhesion

    CN113318220A